ONCLIVE NEWS NETWORK: ON LOCATION WILL BE LIVE AT ESMO THIS WEEK - STAY TUNED FOR MORE INFORMATION!

Dr. Scagliotti on Lung Cancer Treatment-Related Toxicities

Giorgio V. Scagliotti, MD, PhD
Published: Wednesday, Aug 07, 2013

Giorgio V. Scagliotti, MD, PhD, Head, Thoracic Oncology Unit, Department of Clinical and Biological Sciences, University of Turin, San Luigi Hospital, Orbassano, Italy, discusses toxicities related to chemotherapy and surgery in patients with lung cancer.

Pain and other toxicities vary from patient to patient, Scagliotti says, though patients who undergo major surgery are likely to experience more symptoms. Even with a molecularly-targeted therapy approach, side effects are present. Studies with a quality of life assessment nested into the main study have enabled disease-related symptoms to vastly improve.

Skin and GI toxicities have been observed following treatment with EGFR-targeted agents, Scagliotti notes, though more with afatinib than erlotinib or gefitinib. With all of these agents though, patients are still experiencing a survival advantage.

Giorgio V. Scagliotti, MD, PhD, Head, Thoracic Oncology Unit, Department of Clinical and Biological Sciences, University of Turin, San Luigi Hospital, Orbassano, Italy, discusses toxicities related to chemotherapy and surgery in patients with lung cancer.

Pain and other toxicities vary from patient to patient, Scagliotti says, though patients who undergo major surgery are likely to experience more symptoms. Even with a molecularly-targeted therapy approach, side effects are present. Studies with a quality of life assessment nested into the main study have enabled disease-related symptoms to vastly improve.

Skin and GI toxicities have been observed following treatment with EGFR-targeted agents, Scagliotti notes, though more with afatinib than erlotinib or gefitinib. With all of these agents though, patients are still experiencing a survival advantage.


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 18th Annual International Lung Cancer Congress®Oct 31, 20181.5
Clinical Interchange™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations across Lung, Head and Neck, and Bladder CancersOct 31, 20182.0
Publication Bottom Border
Border Publication
x